Novo Nordisk A/S announced that the Chairman of the Board, Göran Ando, has decided not to seek reelection for the Annual General Meeting in March 2018. The Board of Directors has consequently decided to propose current member of the Board of Directors, Helge Lund, to be elected as Chairman of the Board. Helge Lund has in total been a member of the Board of Directors for 2 years and has extensive management experience recently as CEO of BG Group in United Kingdom and as CEO for Statoil in Norway.

The company announced that furthermore, as of 15 February 2018, Karsten Munk Knudsen, currently Senior Vice President of Corporate Finance, will succeed Jesper Brandgaard as Chief Financial Officer. Jesper Brandgaard will continue as Executive Vice President responsible for Biopharma and legal Affairs. Karsten Munk Knudsen started his career in Novo Nordisk in 1999 and has a set finance positions of growing size and complexity throughout the Novo Nordisk value chain.

From 2010 to 2014, he was Corporate Vice President responsible for finance and IT in the U.S. In 2014, he was appointed Vice President -- Senior Vice President responsible for Corporate Finance in Novo Nordisk.